The DMTN Knockout HAP1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the human DMTN gene. This pool of HAP1 cells contains a heterogeneous mix of genetic edits at the DMTN locus, providing a loss-of-function model suitable for studying dematin biology without the need for single-cell cloning. As a polyclonal knockout population, it enables researchers to assess the collective functional consequences of DMTN ablation while mitigating potential off-target effects through cellular diversity.
The host cell line, HAP1, is a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia (CML) cell line. Its haploid karyotype simplifies genetic analyses because loss-of-function mutations are typically expressed without compensation from a second allele. HAP1 cells are widely utilized in genetic perturbation studies, including CRISPR-based screens and targeted gene knockouts, due to their ease of manipulation and consistent growth characteristics. The CML background provides a relevant context for examining cytoskeletal and signaling pathways aberrant in myeloid malignancies.
DMTN encodes dematin, an actin-binding protein that crosslinks actin filaments and anchors them to the spectrin-based membrane skeleton, thereby maintaining cell shape and mechanical stability. Dematin activity is regulated by upstream factors including the GATA1 transcription factor, cAMP-dependent protein kinase (PKA), and protein kinase C (PKC). Upon activation, dematin interacts with beta-actin, alpha/beta spectrin, adducin, protein 4.1R, p55/MPP1, and glycophorin C to organize the spectrin-actin junctional complex at the plasma membrane. Dematin functions within the RhoA/ROCK and Rac1/WAVE signaling networks, which control actin dynamics, and contributes to the GATA1 transcriptional network governing erythroid maturation. Disruption of DMTN impairs these molecular interactions, leading to compromised cytoskeletal integrity and downstream effects on cell adhesion, morphology, and signaling pathways reliant on actin architecture.
In the HAP1 haploid background, knockout of DMTN is expected to produce pronounced cytoskeletal defects due to the lack of a wild-type allele. Cells may exhibit altered cell spreading, compromised membrane stability, and dysregulated actin organization, mirroring the cellular pathology observed in dematin-associated hereditary hemolytic anemias. The model facilitates dissection of dematin??s role in maintaining spectrin-actin network integrity and its interplay with Rho GTPase signaling. Because HAP1 cells retain many signaling pathways found in hematopoietic lineages, this knockout pool is valuable for investigating how dematin loss influences leukemia cell biology and therapeutic vulnerabilities.
Researchers can employ this polyclonal DMTN knockout population in a range of applications, including disease modeling of hereditary spherocytosis and elliptocytosis, actin cytoskeleton research, and genetic screens for modulators of cell morphology. Validation and functional endpoints can be monitored using techniques such as western blotting for total and phosphorylated dematin, immunofluorescence staining of F-actin and spectrin, scanning electron microscopy to assess surface topology, cell spreading and adhesion assays, and co-immunoprecipitation of the spectrin-actin complex. CRISPR-induced mutations should be confirmed by sequencing and RT-qPCR. For further details on using this knockout model, please contact Ascent Research.
